Introduction
============

The maintenance of bone homeostasis is achieved by the delicate balance between osteoblastic bone formation and osteoclastic bone resorption. Uncoordinated activities of osteoblasts and osteoclasts can result in various perturbations in skeletal structure and function thus leading to bone diseases such as Paget\'s disease of bone and osteoporosis [@B1], [@B2]. Estrogen deficiency-induced bone loss, mainly due to enhanced osteoclast activity, plays an essential role in osteoporosis in postmenopausal women, leading to fragility fractures that are often associated with life- threatening mortality and morbidity, as well as massive economic cost to both individuals and society [@B3].

Osteoclasts are large multinucleated cells which are derived from hematopoietic progenitors. The formation of mature osteoclasts is dependent on several crucial factors, including macrophage-colony stimulating factor (M-CSF) and receptor activator of nuclear factor kappa B (NF-κB) ligand (RANKL). Osteoclast precursor cells undergo survival and proliferation in response to the binding of M-CSF to its receptor c-Fms [@B4]. RANKL is an indispensable and sufficient factor for osteoclastogenesis, via its action on RANK receptor [@B5]. After stimulation with RANKL, recruitment of TNF receptor-associated factor 6 (TRAF6) is induced to activate multiple downstream targets including mitogen-activated protein kinases (MAPKs) and NF-κB pathways, leading to activation of c-Fos and nuclear factor of activated T cells 1 (NFATc1) [@B6]-[@B8]. These signaling cascades enable the expression of genes that typify the osteoclast lineage including *Acp5* (encoding tartrate-resistant acid phosphatase \[TRAcP\]), *Ctsk* (encoding cathepsin K), and *Mmp9* (encoding matrix metalloproteinase 9), thus eventually leading to the formation of mature osteoclasts [@B6].

Growing evidence also indicates that intracellular reactive oxygen species (ROS) play a crucial role during osteoclast formation and bone resorption [@B9]-[@B11]. ROS are endogenously produced in osteoclast precursors following stimulation with RANKL, via a signaling cascade involving TRAF6, Rac1, and nicotinamide adenine dinucleotide phosphate (NADPH) oxidase 1 (Nox1)[@B9]. Application of oxidant scavenger like N-acetylcysteine (NAC) or Nox inhibitor such as diphenylene iodonium (DPI), was found to inhibit osteoclastogenesis by suppressing RANKL-mediated ROS production [@B9], indicating ROS are required for osteoclast differentiation. Cellular protective mechanisms against oxidative stressors also include a variety of cytoprotective or antioxidant enzymes, such as heme oxygenase-1 (HO-1), catalase, glutathione- disulfide reductase (GSR), NAD(P)H: quinone reductase (NQO1), and γ-glutamylcysteine synthetase (GCS) [@B12], [@B13]. Antioxidants were shown to attenuate osteoclast formation and bone resorption by enhancing expression of the cytoprotective enzymes [@B14], [@B15]. The downstream targets of ROS in RANKL-mediated signaling still remain unclear; however, a higher level of oxidative stress was suggested to promote osteoclast formation and function through the activation of NF-κB and MAPKs [@B13], [@B16]. In addition, ROS production is highly involved in bone remodeling and bone homeostasis by promoting bone resorption [@B16], [@B17]. Estrogen deficiency-induced osteoporosis is associated with a higher level of oxidative stress and can be prevented by increasing antioxidant defenses [@B18]-[@B20]. Therefore, these findings might provide a rationale for suppressing ROS as a potential strategy for the treatment of osteoporosis.

Pseurotin A (Pse) is a bioactive secondary metabolite originally isolated from *Pseudoeurotium ovalis* [@B21] and later also from several species of Aspergillus [@B22]-[@B24]. A single hybrid polyketide synthase/non-ribosomal peptide synthetase (PKS/ NRPS) [@B25] gene and the *rtfA* gene [@B26] are associated with the biosynthesis of Pse in Aspergillus fumigatus. The expression of Pse is also induced in response to hypoxia [@B27]. So far, Pse has demonstrated potential therapeutic applications due to its immunosuppressive activity [@B28], antibacterial activity [@B29], nematicidal activity [@B30], antiparasitic as well as anticancer activity [@B22]. Furthermore, Pse was found to have antioxidant and radical-scavenging activity, as demonstrated by its ability to scavenge the DPPH (2, 2-diphenyl-1-picrylhydrazyl) radical [@B31].

Given the significant role of ROS on osteoclast formation and function, the potential antioxidant activity as well as other various potential therapeutic applications of Pse, we hypothesized that Pse might inhibit osteoclasts and thus prevent osteoclast-related osteoporosis. In the present study, we assessed the therapeutic effects of Pse on RANKL-induced osteoclastogenesis *in vitro* and ovariectomized (OVX)- induced osteoporosis mouse models *in vivo*, with a focus on determining the antioxidant capacity of Pse as well as elucidating its underlying mechanisms.

Materials and Methods
=====================

Materials and reagents
----------------------

Pse, obtained from SHANGHAI ZZBIO CO., LTD (Shanghai, China), was dissolved in Dimethyl sulfoxide (DMSO) (Sigma-Aldrich, Sydney, NSW, Australia) at a concentration of 100 mM and further diluted to working concentrations with culture medium. DMSO of the same dilution was used as vehicle control. Alpha modified Minimal Essential Medium (a-MEM) and fetal bovine serum (FBS) were purchased from Thermo Fisher Scientific (Scoresby, VIC, Australia). MTS assay kit and luciferase analysis system were purchased from Promega (Sydney, NSW, Australia). Primary antibodies for TRAF6, IκB-α, β-actin, phospho-ERK, ERK, phospho-P38, P38, NFATc1, Integrin αV, cathepsin K, and V-ATPase-d2 were purchased from Santa Cruz Biotechnology (Dallas, CA, USA). Primary antibody for GSR was purchased from Bioss Inc (Woburn, MA, USA). Primary antibodies for HO-1, catalase, phospho-JNK, JNK, and Active Rac1 Detection Kit were purchased from Cell Signaling Technology (Danvers, MA, USA). Primary antibody for vinculin was purchased from Sigma-Aldrich (Sydney, NSW, Australia). Recombinant M-CSF was purchased from R&D Systems (Minneapolis, MN, USA). Recombinant Glutathione *S*-transferase (GST)-rRANKL protein was expressed and purified as previously described [@B32]. Rhodamine Phalloidin, ProLong Gold Antifade Mountant, and 2\',7\'-dichlorodihydrofluorescein diacetate (H~2~DCFDA) were obtained from Thermo Fisher Scientific (Scoresby, VIC, Australia) and 4,6-diamidino-2-phenylindole (DAPI) was purchased from Santa Cruz Biotechnology (Santa Cruz, Dallas, CA, USA). Dihydroethidium (DHE) was purchased from ApexBio (Boston, MA, USA).

*In vitro* osteoclastogenesis assay
-----------------------------------

Fresh bone marrow macrophages (BMMs) from C57BL/6J mice were isolated using methods approved by the University of Western Australia Animal Ethics Committee (RA/3/100/1244) as described [@B16]. In brief, bone marrow was flushed from the femur and tibia and then cultured in α-MEM/10% FBS/Penicillin/streptomycin (complete αMEM). To obtain pure BMMs, non-adherent cells were then collected and cultured in complete αMEM containing M-CSF (50 ng/mL). After a further 3 days in culture, the attached cells were used for experimental purposes. BMMs were plated in 96-well plates at a density of 6 × 10^3^ cells/well overnight. The following day, cells were stimulated with M-CSF and GST-rRANKL (50 ng/mL) in the presence or absence of increasing concentrations of Pse (2.5, 5, 7.5, 10 μM). Medium was replaced every 2 days until osteoclasts formed. The cells were then fixed with 2.5% glutaraldehyde solution for 10 min and stained for tartrate resistant acid phosphatase (TRAcP) enzymatic activity using a leucocyte acid phosphatase staining kit (Sigma-Aldrich, Sydney, NSW, Australia). Cells with more than 3 nuclei were counted as osteoclasts.

Cytotoxicity assay
------------------

BMMs were seeded in 96-well plates at a density of 6 × 10^3^ cells/well and incubated overnight to allow adherence. Cells were then treated with different concentrations of Pse (0, 2.5, 5, 7.5, 10 μM) for 48 h. At the end of the experiment, MTS solution (20 μL/well) was added and the plate was incubated for an additional 2 h. The optical density (OD) was measured by spectrophotometric absorbance at 490nm using a microplate reader (BMG LABTECH, Ortenberg, Germany).

Staining for podosome belts
---------------------------

To visualize podosome belts, BMMs were seeded onto FBS-coated coverslips (5-mm diameter) in 96-well plates and were induced to form osteoclasts, as described above, in the presence of Pse (0, 5, 10 μM). Osteoclasts were then fixed 4% paraformaldehyde (PFA) for 10 min, permeabilized with 0.1% (v/v) Triton X-100 for 10 min and blocked with 3% BSA in PBS for 1h. Cells were then incubated with mouse monoclonal anti-vinculin (1:200) at 4 °C overnight, followed by washing in PBS and incubation with a fluorescent secondary anti-mouse antibody (Alexa Fluor 488, green). F-actin was stained with Rhodamine Phalloidin in the dark for 1 h. After that, cells were washed with PBS, stained with DAPI for 10 min, washed again, and mounted in ProLong Gold Antifade Mountant prior to visualization using a NIKON A1Si confocal microscope (Nikon Corporation, Minato, Tokyo, Japan).

Quantitative real-time PCR
--------------------------

BMMs were cultured in 6-well plates (1 × 10^5^ cells/well) and stimulated with GST- rRANKL and M-CSF in the presence of Pse (0, 5, 10 μM) until osteoclasts formed. Total RNA was isolated from the cells using Trizol reagent (Life Technologies, Sydney, Australia) and single stranded cDNA was prepared from 1 μg of total RNA template using moloney murine leukemia virus (MMLV) reverse transcriptase with oligo-dT primer (Promega, Sydney, NSW, Australia). For relative quantitative real-time PCR (qPCR), SYBR Green PCR MasterMix (Thermo Fisher Scientific, Scoresby, VIC, Australia) was used. The cycling parameters for PCR were set as follows: 94 °C for 10 min, followed by 40 cycles of 95 °C for 15 s, 60 °C for 60 s. The specific primers used are as following: *Ctsk* (forward: 5\'-GGGAGAAAAACCTGA AGC-3\'; reverse: 5\' -ATTCTGGGGACTCAGAGC-3\'), *Acp5* (forward: 5\'-TGTGGCCATCTTTATG CT-3\'; reverse: 5\'-GTCATTTCTTTGGGGCTT-3\'), *Atp6v0d2* (Forward: 5′-GTGAGACCTTGGAA GACCTGAA-3′; Reverse: 5′-GAGAAATGTGCTCAGGGGCT-3′), *Mmp9* (Forward: 5′-CGTGTCTG GAGATTCGACTTGA-3′; Reverse: 5′-TTGGAAACTCACACGCCAGA-3′), *Nfatc1* (Forward: 5′- CA ACGCCCTGACCACCGATAG-3′; Reverse: 5′-GGCTGCCTTCCGTCTCATAGT- 3′), *C-fos* (Forward: 5′- GCGAGCAACTGAGAAGAC-3′; Reverse: 5′- TTGAAACCCGAGAACATC- 3′), *Hmbs* (Forward: 5′- AAGGGCTTTTCTGAGGCACC -3′; Reverse: 5′-AGTTGCCCATCTTTCATCACTG- 3′), *Hprt1* (Forward: 5′- TCAGTCAACGGGGGACATAAA-3′; Reverse: 5′-GGGGCTGTACTGCTTAACCAG - 3′). The qPCR procedure was performed on a ViiA 7 Real-time PCR machine (Applied Biosystems, Warrington, Cheshire, UK). Target gene expression levels were normalized to average expression of *Hprt1* and *Hmbs*.

Hydroxyapatite resorption assay
-------------------------------

To determine whether Pse affects osteoclast function, hydroxyapatite resorption assay was performed as described previously [@B15], [@B33], [@B34]. BMMs were plated in 6-well collagen-coated plates (Corning Inc., Corning, NY, USA) in complete αMEM with M-CSF at a density of 1 x 10^5^ cells/well. The following day cells were stimulated with 50 ng/mL GST-RANKL until osteoclasts began to form. Cells were then gently detached using cell dissociation solution (Sigma-Aldrich, Sydney, NSW, Australia) and an equal number of cells were seeded into each well of hydroxyapatite-coated plate (Corning Inc., Corning, NY, USA). Cells were treated with Pse at increasing concentrations (0, 5, 10 μM) in complete αMEM containing 50 ng/mL GST-rRANKL and M-CSF. After 48 h incubation, half of the wells for each group were washed with 10% bleach solution to remove cells and the images of hydroxyapatite resorption areas were captured using a using a Nikon microscope (Nikon Corporation, Minato, Tokyo, Japan) and quantified using Image J software (NIH, Bethesda, Maryland, USA). The remaining wells were fixed and stained for TRAcP activity as above to count the number of osteoclasts. The resorbed area per well and the percentage of resorbed area per osteoclast were used to quantify the osteoclast activity.

Detection of intracellular ROS production
-----------------------------------------

The intracellular production of ROS was measured as described previously [@B9]. Briefly, after stimulation with GST-rRANKL (50 ng/mL) in the absence or presence of Pse at stated concentrations (5, 10 µM), BMMs were then incubated in Hank\'s balanced salt solution containing 5 mM H~2~DCFDA for 1 h. Upon oxidation, the nonfluorescent H~2~DCFDA was converted to the highly fluorescent 2\',7\'-dichlorofluorescein (DCF). The fluorescence of DCF was measured at an excitation wavelength of 488 nm and an emission wavelength of 515-540 nm using a NIKON A1Si confocal microscope. Cells images were also captured by digital interference contrast (DIC). The mean fluorescence intensity for each cell and the number of ROS-positive cells per field were analyzed using Image J software.

Luciferase reporter assays of NF-κB or NFATc1
---------------------------------------------

RAW264.7 cells (ATCC, Manassas, Virginia, USA), stably transfected with an NF-κB responsive luciferase construct [@B35] and an NFATc1 responsive luciferase reporter construct [@B36], were seeded in 48-well plates at a density of 1.5 × 10^5^ cells/well or 5 × 10^4^ cells/ well overnight, respectively. Cells were then pre-treated with Pse for 1 h and stimulated with GST-rRANKL (50 ng/mL) for 6 h and 24 h respectively. At the end of the time points, cells were lysed, and luciferase activity was measured using the luciferase reporter assay kit (Promega, Sydney, NSW, Australia) and a luminescence reader (BMG LABTECH, Ortenberg, Germany).

Western blot Assay
------------------

BMM cells were seeded in 6-well plates (1 × 10^5^ cells/well) and stimulated with GST- rRANKL and M-CSF in the presence or absence of Pse of indicated concentrations for the stated times. Cells were lysed in radioimmunoprecipitation (RIPA) lysis buffer to harvest protein. For GTP-Rac1 detection, cell lysates were collected and incubated with GST-Human PAK1-PBD fusion protein that binds to GTP-bound Rac1 using Active Rac1 Detection Kit (Cell Signaling Technology, Danvers, MA, USA). Protein was separated by SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to a nitrocellulose membrane (GE Healthcare, Silverwater, Australia). Non-specific binding was blocked by incubation in 5% skim milk powder and the membrane was then incubated with primary antibodies (1:1000) with gentle shaking overnight at 4 ℃. The next day, membranes were washed and incubated with horseradish peroxidase (HRP)-conjugated secondary antibodies at room temperature for 1 h. Antibodies were detected with enhanced chemiluminescence substrate (PerkinElmer, Waltham, MA, USA). Images were acquired on an Image-quant LAS 4000 (GE Healthcare, Silverwater, NSW, Australia) and analyzed by ImageJ software.

Ovariectomized (OVX)-induced osteoporosis mouse model
-----------------------------------------------------

All *in vivo* experimental procedures were approved by the Institutional Animal Ethics Committee of Sir Run Run Shaw Hospital. Eighteen C57BL/6J mice (females; 18.6 ± 1.4 g, 11 weeks old) were supplied by Animal Experiment Center of Sir Run Run Shaw Hospital (Hangzhou, Zhejiang, China). All mice were randomly divided into three groups: sham group (n=6), OVX group (n=6), and OVX+Pse (5 mg/kg) group (n=6). Bilateral ovariectomy was carried out to induce osteoporosis under chloral hydrate anesthesia for the mice in OVX group and OVX+Pse group, a sham procedure in which the ovaries were only exteriorized but not resected was performed for the mice in sham group. All mice had a 1-week-recovery after operations, then the mice in the OVX +Pse group were administrated an intraperitoneal injection of Pse at 5 mg/kg every 2 days for 6 weeks. The mice in the sham and OVX groups were intraperitoneally injected with vehicle (1% DMSO in PBS) as a control. ROS production *in vivo* was determined using DHE following previously described protocols with modifications [@B37], [@B38]. In brief, 24h before killing, each mouse received a 200-μL intravenous injection of DHE at 25 mg/kg.

Micro-CT scanning and analysis
------------------------------

After sacrifice, the femurs were collected and fixed in 10% neutral buffered formalin for 24 h and the excess soft tissue was removed. Left femurs were scanned using a Skyscan 1176 micro-CT instrument (Bruker microCT, Kontich, Belgium) using the following settings: source voltage, 50 kV; source current, 500 μA; AI 0.5 mm filter; pixel size 9 μm; rotation step, 0.4 degree. The images were then reconstructed with NRecon software (Bruker microCT, Kontich, Belgium) using the following settings: ring artefact correction, 7; smoothing, 2; beam hardening correction, 40%. A refined volume of interest was generated 0.5 mm above the growth plate of the distal femur and 1 mm in height. The trabecular bone region of interest (ROI) within this volume was manually defined and bone parameters within this ROI were all determined using a constant threshold (50 \~ 255) for binarization of the trabecular bone. The following parameters, including bone volume per tissue volume (BV/TV), trabecular number (Tb.N), connectivity density (Conn.Dn), and trabecular thickness (Tb.Th), were analyzed by the program CTAn (Bruker microCT, Kontich, Belgium). Cortical bone analysis was performed in the mid shaft (4 mm below the growth plate with a height of 1 mm) and a constant threshold (100\~ 255) for binarization was used.

Bone histomorphometry analysis
------------------------------

Following micro-CT analysis, femurs were decalcified in 14% EDTA (Sigma-Aldrich, Sydney, NSW, Australia) at 37 ℃ for 7 days, and then embedded into paraffin for sectioning. Hematoxylin and eosin (H&E) staining and TRAcP activity staining were performed. Section images were acquired using Aperio Scanscope (Mt Waverley, VIC, Australia), and bone histomorphometric analyses were performed using BIOQUANT OSTEO software (Bioquant Image Analysis Corporation, Nashville, TN, USA).

For *in vivo* ROS fluorescence detection, cryosections of bone tissues were prepared as previously described [@B39]. Fresh bone tissues were dissected, cleaned and immediately fixed in 4% paraformaldehyde (Sigma-Aldrich, Sydney, NSW, Australia) solution at 4 ℃ for 4 h. Next, decalcification was carried out with 0.5 M EDTA overnight at 4 ℃ under constant rotation, after which the EDTA was exchanged for cryoprotective solution composed of 20% sucrose and 2% polyvinylpyrrolidone (PVP) (Sigma-Aldrich, Sydney, NSW, Australia) for 24 h. Finally, the resultant tissues were embedded and frozen in 8% gelatin in the presence of 20% sucrose and 2% PVP. 5 μm sections were generated and air-dried at room temperature prior to permeabilization for 10 min in 0.3% Triton X-100 (Sigma-Aldrich, Sydney, NSW, Australia). Nuclei were stained with DAPI for 30 min. After washing with PBS, sections were mounted, and coverslips were sealed with nail polish. A NIKON A1Si confocal microscope (Nikon Corporation, Minato, Tokyo, Japan) was used for imaging. The fluorescence intensity of 6 random areas of each group were quantified and analyzed using NIS-Elements software (Nikon Corporation, Minato, Tokyo, Japan).

Statistical analysis
--------------------

Each experiment was repeated at least three times. All quantitative data are presented as mean ± standard deviation (SD). Statistical significance was determined by Student\'s t test. A p-value of less than 0.05 was considered to be significant.

Results
=======

Pse suppresses RANKL-induced osteoclastogenesis *in vitro*
----------------------------------------------------------

The chemical structure and formula of Pse are shown in **Figure [1](#F1){ref-type="fig"}A**. To identify the effect of Pse on osteoclastogenesis, BMMs were seeded in 96-well plates and treated with both M-CSF and RANKL in the presence or absence of various concentrations of Pse as indicated. The purity of isolated precursor BMMs was approximately 99%, as assessed by flow cytometry for CD11b (**Figure [S1](#SM0){ref-type="supplementary-material"}**). Numerous TRAcP-positive multinucleated osteoclasts formed in the RANKL-induced control group (without Pse), whereas increasing concentrations of Pse exerted a dose-dependent inhibition on osteoclastogenesis (**Figure [1](#F1){ref-type="fig"}B and C**). To determine any potential cytotoxicity of Pse on BMMs, MTS assay was performed to assess cell viability. Pse was found to have no effect on BMM proliferation over the concentrations used in this study (**Figure [1](#F1){ref-type="fig"}D**). To examine which stage of osteoclastogenesis was affected, cells were treated with 10 μM Pse at indicated time phases (**Figure [1](#F1){ref-type="fig"}E**). Pse was found to predominantly exert its suppressive effect during mid-late stage (Day 3-6) of osteoclast differentiation, rather than early stage (Day 1-3) (**Figure [1](#F1){ref-type="fig"}F**).

Pse affects podosome belt formation and inhibits osteoclast-specific genes expression
-------------------------------------------------------------------------------------

Cells were co-stained with rhodamine-phalloidin and anti-vinculin to visualize podosome belt formation and morphological changes in cells treated with or without Pse. As shown in **Figure [2](#F2){ref-type="fig"}A**, after RANKL stimulation, well-defined podosome belts with intact nuclei formed in mature osteoclasts. In contrast, smaller osteoclasts with fewer nuclei were observed after Pse treatment (5, 10 μM) (**Figure [2](#F2){ref-type="fig"}B and C**).

Several osteoclast-specific genes, including *c-fos*, *Nfatc1*, *Ctsk*, *Acp5*, *Atp6v0d2*, and *Mmp9* are upregulated in BMMs when osteoclast differentiation is induced. We examined these genes at mRNA level using quantitative PCR to observe how Pse affected osteoclast-specific genes expression and found that their expression was inhibited during RANKL-induced osteoclastogenesis following the addition of Pse (**Figure [2](#F2){ref-type="fig"}D-I**). Collectively, these results further confirmed that Pse suppressed the expression of osteoclast-specific genes and thus osteoclastogenesis *in vitro*.

Pse inhibits osteoclast resorptive function
-------------------------------------------

We next determined whether Pse has an effect on osteoclast resorptive activity using hydroxyapatite-coated plates. A reduction in the number of osteoclasts and the resorption area were observed at both Pse concentrations (5, 10 μM) (**Figure [3](#F3){ref-type="fig"}A and B**). In addition, following normalization of resorption area to the number of osteoclasts, a dose-dependent inhibitory effect on osteoclast resorptive function was observed as compared to the control group (**Figure [3](#F3){ref-type="fig"}C**).

Pse reduces RANKL-induced intracellular ROS level in BMMs
---------------------------------------------------------

To investigate whether RANKL-induced ROS production during osteoclast differentiation was reduced by Pse, ROS level was visualized using a cell-permeable, oxidation-sensitive dye H~2~DCFDA. ROS oxidation of this dye was detected as a fluorescent signal derived from the oxidation product DCF using confocal microscopy. The intensity of DCF fluorescence was significantly decreased in a dose-dependent manner in BMMs when stimulated with M-CSF and RANKL in the presence of Pse (5, 10 μM) (**Figure [4](#F4){ref-type="fig"} A-C**). Therefore, our results indicated that Pse inhibited osteoclast formation and activity via suppressing ROS.

Pse suppresses intracellular ROS level by down-regulating the TRAF6/Rac1/Nox1 signaling cascade as well as enhancing expression of antioxidant enzymes
------------------------------------------------------------------------------------------------------------------------------------------------------

To determine whether Pse affects ROS generation, the activation level of Nox1, known as a major contributing factor in ROS generation [@B9], [@B40], was investigated using western blot. BMMs were incubated with RANKL for 2 days in the absence or presence of Pse at different concentrations as indicated. Nox1 expression was significantly up-regulated by RANKL, but dose-dependently inhibited by Pse at the concentrations of 2.5-10 μM (**Figure [4](#F4){ref-type="fig"} D and F**). TRAF6 and GTP-Rac1 are required for the Nox1 activation, we therefore examined whether Pse inhibited Nox1 by attenuating TRAF6 and GTP-Rac1. Adaptor protein TRAF6 expression was augmented by RANKL and showed a trend of down-regulation at high concentrations (10 μM), which was not significant (**Figure [4](#F4){ref-type="fig"} D and E**). GTP-bound Rac1 is a cytosolic component of Nox1 and is responsible for Nox1 activation. As shown in **Figure [1](#F1){ref-type="fig"}G and H**, GTP-Rac1 activation was significantly enhanced after 5 min and 15 min of RANKL stimulation but was attenuated by Pse treatment in a dose-dependent manner. Next, to examine whether Pse is able to scavenge ROS by up-regulating antioxidant enzymes, the expression of antioxidant enzymes including HO-1, catalase, and GSR were examined. As shown in **Figure I and J**, the expression of HO-1 was reduced by RANKL stimulation but was recovered and enhanced dose- dependently by Pse treatment. Similarly, Pse also enhanced the expression levels of catalase (**Figure [4](#F4){ref-type="fig"} I and K**) and GSR (**Figure [4](#F4){ref-type="fig"} I and L**). Taken together, these data mechanistically suggest that Pse suppresses RANKL-induced intracellular ROS level via inhibition of ROS generation as well as the enhancement of ROS scavenging.

Pse interferes with RANKL-induced activation of NF-κB and MAPK pathways
-----------------------------------------------------------------------

NF-κB and MAPK pathways are regarded as the main signaling pathways activated during osteoclastogenesis [@B6], and RANKL-induced ROS generation may trigger these signaling events. In order to further explore whether Pse blocked ROS activated osteoclastogenesis via attenuating NF-κB and MAPK signaling, we investigated these two pathways using Western Blot and luciferase assay. For the NF-κB pathway, we analyzed the expression of IκB-α. NF-κB transcription factors are bound to IκB-α and retained in an inactive state, these are activated and released when IκB-α is degraded after stimulation with RANKL [@B41]. Within 60 minutes of stimulation with RANKL, IκB-α degradation was significantly inhibited by Pse (**Figure [5](#F5){ref-type="fig"}A and B**), thus indicating failure to activate NF-κB signaling. Consistent with inhibition of IκB-α degradation, the results of luciferase assay showed the activation of NF-κB was significantly inhibited by treatment with Pse (**Figure [5](#F5){ref-type="fig"}C**). For the MAPK signaling pathway, as shown in **Figure [5](#F5){ref-type="fig"}D**, phosphorylation of ERK (**Figure [5](#F5){ref-type="fig"}E**), p38 (**Figure [5](#F5){ref-type="fig"}F**), and JNK (**Figure [5](#F5){ref-type="fig"}G**) relative to total ERK, total p38, and total JNK was suppressed significantly by Pse treatment in BMMs. Collectively, these data suggested Pse had an inhibitory effect on both NF-κB and MAPK activation pathways mediated by RANKL.

Pse attenuates NFATc1 activity and downstream factors
-----------------------------------------------------

NFATc1 acts as the master transcriptional regulator of osteoclastogenesis [@B7]. In this study, RAW264.7 cells stably expressing an NFATc1-driven luciferase reporter gene were used to measure the NFATc1 transcriptional activity. After stimulation with RANKL, NFATc1 activity was very highly elevated (**Figure [5](#F5){ref-type="fig"}H**). In contrast, NFATc1 activity was abrogated significantly in a dose-dependent manner after pre-treatment with Pse (2.5, 5, 10 μM) (**Figure [5](#F5){ref-type="fig"}H**). NFATc1 expression was also found to be suppressed over the course of osteoclast differentiation using Western Blot assay (**Figure [5](#F5){ref-type="fig"}I and J**). In addition, our results showed that Pse abrogates the elevation of integrin αV (**Figure [5](#F5){ref-type="fig"}K**), cathepsin K (**Figure [5](#F5){ref-type="fig"}L**), and V-ATPase-d2 (**Figure [5](#F5){ref-type="fig"}M**), which are all downstream proteins needed for osteoclast formation and function. Consequently, Pse treatment strongly inhibits NFATc1 activity, thus affecting downstream protein expression.

Pse prevents OVX-induced bone loss
----------------------------------

Our results established that Pse has inhibitory effects on osteoclast formation and function *in vitro*. The potential of Pse to act as a prophylactic agent to protect against osteoclast-related bone disease *in vivo* was further explored using an OVX-induced osteoporosis mice model. Mice were either OVX or sham operated and were then intraperitoneally injected with either Pse at a concentration of 5 mg/kg every 2 days, or vehicle only for 6 weeks post-surgery (**Figure [6](#F6){ref-type="fig"}A**). No adverse events or fatalities were recorded after the OVX procedure and Pse administration. Furthermore, there were no observable effects of Pse on body weight in treated mice relative to non-treated mice (**Figure [S5](#SM0){ref-type="supplementary-material"}A**). Micro-CT confirmed that Pse prevented the extensive bone loss induced by the OVX procedure in mice femurs (**Figure [6](#F6){ref-type="fig"}B**). Quantitative analysis of bone parameters also confirmed increased BV/TV, Tb.N and Conn.Dn in Pse treated group relative to the OVX mice without Pse treatment (**Figure [6](#F6){ref-type="fig"}C-E**). However, Tb.Th remained unchanged in this study (**Figure [6](#F6){ref-type="fig"}F**). Consistently, histological examination showed that Pse reduced the extent of bone loss induced by OVX (**Figure [6](#F6){ref-type="fig"}G**). Quantification of H&E staining demonstrated that the bone volume and bone surface were both well maintained in Pse treated group compared with non-Pse treated OVX mice (**Figure [6](#F6){ref-type="fig"}H and I**). Cortical bone related parameters, including cortical thickness (Ct.Th), total cross-sectional area (Tt.Ar), cortical bone area (Ct.Ar), and cortical area fraction (Ct.Ar/Tt.Ar), were also analyzed (**Figure [S5](#SM0){ref-type="supplementary-material"}B-F**). Pse showed no effect on cortical bone.

Pse reduces osteoclasts and ROS production in the OVX mouse model
-----------------------------------------------------------------

Histological staining using TRAcP was performed on femur sections to examine the number of osteoclasts *in vivo*. As shown in **Figure [7](#F7){ref-type="fig"}A**, the OVX procedure led to an increased number of TRAcP- positive osteoclasts, whereas Pse treatment prevented the increase of osteoclast number *in vivo*. This was supported by quantification of osteoclast parameters, demonstrating a reduction in the number and surface area of osteoclasts on the bone surface in Pse treated mice (**Figure [7](#F7){ref-type="fig"}B and C**). In addition, as Pse exhibited *in vitro* anti-oxidant activity, *in vivo* ROS level was also assessed in cryosections of bone tissue using DHE, a probe that detects ROS. Consistent with previous publications [@B42], [@B43], ROS fluorescence intensity was highly elevated due to OVX procedure and Pse dramatically reversed the ROS production within the bone marrow microenvironment (**Figure [7](#F7){ref-type="fig"} D and E**). Taken together, these data indicated that Pse prevented OVX-induced bone loss *in vivo* by scavenging ROS thus inhibiting osteoclast activity.

Discussion
==========

Osteoporosis is a skeletal disease which is characterized by low bone mass, leading to reduced bone strength and susceptibility to fracture. It is more frequently diagnosed in the postmenopausal population majorly due to excessive osteoclast activity. Therefore, osteoclasts remain as the major target in dealing with osteoporosis. Current clinically available therapies for osteoporosis such as estrogen replacement, bisphosphonates, and denosumab are effective but have limitations and side-effects including increased risk of breast cancer, osteonecrosis of the jaw, and atypical femur fracture [@B44], [@B45]. A search for novel alternative drugs is always required for the improved treatment of osteoporosis. In the present study, we elucidated for the first time that Pse inhibited osteoclastogenesis *in vitro* and prevented the development of OVX-induced osteoporosis *in vivo* via suppressing ROS level.

Firstly, osteoclastogenesis assay and hydroxyapatite resorption assay *in vitro*, showed Pse as a potentially novel therapy for osteoclast-related bone disease. Further, we investigated the mechanisms underlying this inhibitory effect on osteoclast formation and function, especially regarding the intracellular ROS level, NF-κB pathway, MAPK pathway, and NFATc1.

Upon stimulation with RANKL, intracellular ROS level was hugely suppressed by Pse treatment, which was accompanied by the reduced activation of NF-κB and MAPKs, leading to the subsequent attenuation of NFATc1. The level of intracellular ROS depends on the balance between the rate of production and the rate of scavenging. ROS are generated during osteoclastogenesis through a signaling cascade including TRAF6, Rac1, and Nox1 [@B9]. Nox1-mediated ROS production was found to regulate RANKL-induced signaling and is required for osteoclastogenesis [@B9], [@B40]. Therefore, we hypothesized that the down-regulated ROS signaling might be partly due to the inhibition of Nox1. Indeed, Pse effectively attenuated Nox1 expression via the suppression of GTP-Rac1. To scavenge oxidative stress and maintain redox homeostasis, a wide range of antioxidant enzymes are induced. Several ROS scavengers were determined to be upregulated by Pse in this study, such as HO-1, catalase, and GSR. HO-1 induction may act as a defense mechanism to catalyze heme liberated by oxidants [@B46]. Catalase plays a key role in converting hydrogen peroxide into water and oxygen [@B47]. GSR converts glutathione disulphide back to glutathione in an NADPH-consuming process and GSR inhibitor was also found to induce the activation of the NF-κB pathway [@B48]. The mechanisms behind the upregulation of antioxidant enzymes still remain unclear. Nuclear factor- erythroid 2 related factor 2 (Nrf2) is regarded as an important redox-sensitive transcription factor that positively regulates antioxidant enzymes [@B12], [@B13]. RANKL stimulation attenuated the gene expression of *Nrf2* to favour ROS signalling, whereas Pse treatment recovered and upregulated *Nrf2* expression dose dependently (**Figure [S4](#SM0){ref-type="supplementary-material"}**), suggesting that Pse may upregulate antioxidant enzymes at least in part via augmenting *Nrf2*. Taken together, Pse attenuates the ROS level by suppressing ROS production as well as enhancing ROS scavenging.

Accumulating evidence suggests that RANKL- induced ROS signaling regulates MAPK and NF-κB activation [@B9], [@B18], [@B49]-[@B51]. NF-κB signaling serves a crucial role and appears to be the first event in early osteoclast development from precursors, followed by c-Fos and NFATc1 activation [@B7]. Loss of NF-κB signaling in mice leads to an osteopetrotic bone phenotype due to a defect of osteoclastogenesis [@B52]. Tumor necrosis factor α (TNFα)-induced NF-κB activation is redox-dependently regulated through the dynein light chain LC8 [@B49]. ROS is able to oxidize LC8 to a homodimer linked by a disulphide bond between the Cys^2^ residues of each subunit, which promotes its dissociation from IκBα and thereby allows IκBα\'s phosphorylation and degradation by IκB kinase (IKK), thus releasing NF-κB dimers to translocate to nucleus [@B49]. In our study, Pse treatment effectively suppressed RANKL-induced IκB-α degradation, as demonstrated by a higher expression level of IκB-α in the Pse treated group, suggesting the involvement of IκB-dependent inactivation of NF-κB in the inhibitory effect of Pse on osteoclast formation. Furthermore, luciferase assay results consistently supported the inhibitory effect of Pse on NF-κB transcriptional activation.

The MAPK pathways, including three major MAPK family members (ERKs, JNKs, and p38), are also important signaling events involved in osteoclast differentiation stimulated by RANKL [@B6]. ERK is crucial for the survival of osteoclasts [@B53], [@B54]. Similarly, JNK and p38 are also phosphorylated during osteoclastogenesis in response to RANKL stimulation [@B54], [@B55]. MAPKs are activated by MAPK kinases through phosphorylation of tyrosine and threonine and inactivated by MAPK phosphatases (MKPs) through dephosphorylation [@B56]. ROS may act as a physiologic second messenger and oxidize tyrosine phosphatases, thus inhibiting MKPs and subsequently activating MAPKs [@B9], [@B57]. In the present study, the Western Blot results showed that Pse comprehensively attenuated the phosphorylation of ERK, JNK, and p38 thus achieving its inhibitory effects. Thus, ROS is suggested to incorporate into the activation of NF-κB and MAPKs during osteoclastogenesis.

NFATc1 is well-known as a master transcriptional regulator of terminal osteoclast differentiation, and its initiation is regulated in an auto-amplification loop to maintain robust expression by binding to its own promoter [@B8]. NFATc1 modulates the expression of osteoclast downstream gene expression, and NFATc1- deficiency results in inhibition of osteoclastogenesis *in vitro* and osteopetrosis *in vivo* [@B58]. Here, our data implicated that the expression level and transcriptional activity of NFATc1 were reduced by Pse following RANKL stimulation. The mechanism behind the reduction of NFATc1 still remains unclear. It could result from the suppression of upstream NF-κB and MAPK signaling or a direct intervention of NFATc1 activation. We further demonstrated that Pse suppressed the expression of osteoclast-specific genes, including *Ctsk*, *Acp5*, *Atp6v0d2*, and *Mmp9,* which are regulated by NFATc1 directly or indirectly [@B59], [@B60], and participate in osteoclast formation and their bone resorptive function. C-Fos, which cooperates with NFATc1 in the context of activator protein 1 (AP-1) and contributes to osteoclast differentiation [@B61], was also found to be inhibited by Pse treatment at mRNA expression level.

Based on these convincing *in vitro* results, an OVX mouse model was further used to evaluate whether Pse has therapeutic effects *in vivo* through its antioxidant activity. It is interesting to note that oxidative stress status has a negative correlation with osteoporotic status. OVX rats were found to have higher oxidative stress in the femurs accompanied by a decreased activity of antioxidant systems compared to sham-operated control rats [@B42], [@B62]. Furthermore, Altindag et al. found that the oxidative stress index values and total plasma oxidant status in osteoporotic postmenopausal women was higher than that in the healthy group [@B43]. The development of osteoporosis is at least partly due to the imbalance between antioxidant defenses and oxidative stress. This compelling evidence provides a new insight into a potential approach for the treatment of postmenopausal osteoporosis via suppressing oxidative stress.

Our results indicated that Pse exhibited a significant protective effect on OVX-induced bone loss in mice by scavenging ROS. A previous study on ROS detection in bone used direct staining on histological sections to assess ROS level [@B16]. However, the stability of ROS level is likely to be highly variable using this method due to the lengthy tissue fixation and processing times. In this study, a ROS probe was intravenously injected 24h prior to euthanasia, which allowed DHE to be distributed to cells and tissues via the circulation. DHE is a probe that is particularly sensitive to superoxide anion levels and it was previously reported as an *in vivo* marker for ROS [@B37]*.* The imaging of bone tissue remains challenging because of its calcified nature. Herein, a protocol of mild fixation, decalcification, and cryo-sectioning was used to process the bone samples, which was able to effectively preserve cellular morphology and tissue architecture [@B39]. To our knowledge, this is the first time that DHE was used as a ROS probe to detect ROS *in vivo* using histological sections in an OVX model. Our data showed that ROS level within bone marrow were dramatically suppressed in the Pse treated group, which was accompanied by a reduced number of TRAcP-positive osteoclasts. The prevention of bone loss by Pse was thought to be due to its suppression of oxidative stress and subsequent compromised osteoclast formation and function. However, this probe is not cell or tissue-specific, this data only indicated the total ROS level in bone marrow microenvironment, osteoclast-specific ROS in this study still remains to be further investigated.

In summary, this study has demonstrated for the first time that Pse can suppress intracellular ROS level by inhibiting RANKL-induced ROS production and enhancing expression of antioxidant enzymes, which attenuates the activation of MAPK and NF-κB pathways, subsequently leading to attenuation of NFATc1 as well as its downstream proteins (**Figure [8](#F8){ref-type="fig"}**). These signaling events contribute to decreased osteoclast formation and bone resorptive function *in vitro*. Additionally, Pse was also found to prevent estrogen deficiency-induced osteoporosis *in vivo* via suppressing oxidative stress in the bone marrow microenvironment. Therefore, Pse may serve as a novel candidate or an alternative therapeutic treatment for osteoclast-related bone disease such as osteoporosis.
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:   bone marrow macrophages
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:   2\',7\'-dichlorofluorescein
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:   dihydroethidium

FBS

:   fetal bovine serum
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GSR

:   glutathione-disulfide reductase

GTP

:   Guanosine-5\'-triphosphate

H~2~DCFDA

:   2\',7\'-dichlorodihydrofluorescein diacetate

HO-1

:   heme oxygenase-1

IKK

:   IκB kinase

MAPKs

:   mitogen-activated protein kinases

M-CSF

:   macrophage-colony stimulating factor

*Mmp9*

:   matrix metallopeptidase 9

NADPH

:   nicotinamide adenine dinucleotide phosphate

NAD(P)H

:   quinone reductase (NQO1)

NFATc1

:   nuclear factor of activated T cells 1

NF-κB

:   nuclear factor-κB

NOX

:   NADPH oxidase

PBS

:   phosphate buffered saline

PCR

:   polymerase chain reaction

Pse

:   Pseurotin A

PVP

:   polyvinylpyrrolidone

OVX

:   ovariectomized

RANKL

:   receptor activator of nuclear factor‐κB ligand

Rac1

:   Ras- related C3 botulinum toxin substrate 1

ROS

:   reactive oxygen species

Tb.N

:   trabecular number

TNF

:   tumor necrosis factor

Tb.Th

:   trabecular thickness

TRAcP

:   tartrate resistant acid phosphatase

TRAF6

:   TNF receptor-associated factor 6.

![**Pse suppresses RANKL-induced osteoclastogenesis *in vitro*. (A)** The chemical structure and formula of Pse. **(B)** Representative images of TRAcP staining showing that Pse inhibited osteoclastogenesis dose-dependently. BMMs were stimulated with RANKL for 5 days in the absence or presence of indicated concentrations of Pse. **(C)** Quantification of TRAcP-positive multinucleated cells (nuclei \>3) (n=3 per group). **(D)** Effects of Pse on BMM viability after 48 h treatment as measured by MTS assay (n=3 per group). **(E)** Representative images of TRAcP staining showing BMMs treated with Pse for the indicated days during osteoclastogenesis. **(F)** Quantification of TRAcP-positive multinucleated cells treated with Pse in different time periods (n=3 per group). All bar graphs are presented as mean ± SD. \*p\<0.05, \*\*p\<0.01 compared with control group (without Pse treatment). Scale bar = 200 µM. BMMs, bone marrow macrophages; OD, optical density; Pse, Pseurotin A; RANKL, receptor activator of nuclear factor‐κB ligand; TRAcP, tartrate-resistant acid phosphatase](thnov09p1634g001){#F1}

![**Pse affects podosome belts formation and inhibits osteoclast-specific genes expression. (A)** Representative images showing the impaired podosome belts formation in osteoclasts treated with Pse. Vinculin (green), F-actin (red) and nuclei (blue) staining of osteoclasts on glass coverslip and observed by confocal microscopy. Overlapping staining of vinculin and F-actin is shown in yellow. **(B)** Quantification of the nuclei number per osteoclast (n=16 per group). **(C)** Quantification of the relative area of osteoclast (n=16 per group). **(D-I)** qPCR analysis of osteoclast-specific genes expression of *c-fos*, *Nfatc1*, *Ctsk*, *Acp5*, *Atp6v0d2*, and *Mmp9* relative to *Hprt1* and *Hmbs* in BMMs stimulated with RANKL for 5 days in the presence of Pse (n=3 per group). All bar graphs are presented as mean ± SD. \*\*p\<0.01 compared with the control group (treated with RANKL but without Pse). Scale bar = 200 µM. *Acp5*, acid phosphatase 5, tartrate resistant;*Atp6v0d2*, ATPase H+ Transporting V0 Subunit D2; BMMs, bone marrow macrophages;*c-fos*, Proto-oncogene C-Fos; *Ctsk*, cathepsin K; *Mmp9,* matrix metallopeptidase 9;*Nfatc1*, nuclear factor of activated T cells 1; PCR, polymerase chain reaction; Pse, Pseurotin A; RANKL, receptor activator of nuclear factor‐κB ligand; TRAcP, tartrate-resistant acid phosphatase](thnov09p1634g002){#F2}

![**Pse inhibits osteoclast resorptive function. (A)** Representative images showing the osteoclastogenesis and hydroxyapatite resorption in each group. Osteoclasts were seeded in hydroxyapatite-coated plates and treated by RANKL with or without Pse. Half of the wells for each group were stained by TRAcP or washed with 10% bleach solution. **(B-C)** Quantification of resorbed hydroxyapatite area per well and resorbed area per osteoclast in each group (n=3 per group). All bar graphs are presented as mean ± SD. \*p\<0.05, compared with control. Scale bar = 200 µM. Pse, Pseurotin A; RANKL, receptor activator of nuclear factor‐κB ligand; TRAcP, tartrate-resistant acid phosphatase](thnov09p1634g003){#F3}

![**Pse attenuates RANKL-induced ROS generation in vitro. (A)** Representative confocal images of RANKL-induced ROS generation in BMMs with or without pre-treatment of Pse. Intracellular ROS generation reacted with the cell permeant, oxidation-sensitive dye H~2~DCFHDA and was detected in the form of highly fluorescent DCF. The lower panel is a merge of DCF fluorescence and confocal digital interference contrast (DIC) images. **(B)** Quantification of DCF fluorescence intensity averaged on cells of each well (n=3 per group). **(C)** Quantification of the number of ROS-positive cells per field (n=3). **(D)** Representative Western Blot images of the effects of Pse on TRAF6 and Nox1 expression. BMMs were stimulated with RANKL (50 ng/mL) in the absence or presence of Pse (2.5, 5, 10 μM) for 2 days before protein collection for Western Blot. **(E and F)** Quantification of the ratios of band intensity of TRAF6 and Nox1 relative to β-actin (n=3 per group). **(G)** Representative Western Blot images of the effects of Pse on GTP-Rac1. BMMs were pretreated with Pse at indicated concentrations and were then stimulated with RANKL for 0, 5, and 15 min. Cell lysates were collected and incubated with GST-Human PAK1-PBD fusion protein that binds to GTP-bound Rac1. Rac1 activation levels were then detected with anti-Rac1 antibody. **(H)** Quantification of the ratios of band intensity of GTP-Rac1 relative to Rac1 (n=3 per group). **(I)** Representative Western Blot images of the effects of Pse on expression of antioxidant enzymes, including HO-1, Catalase, and GSR. **(J-L)** Quantification of the ratios of band intensity of HO-1, Catalase, and GSR relative to β-actin (n=3 per group). All bar graphs are presented as mean ± SD. \*p\<0.01, \*\*p\<0.01 relative to RANKL-induced control group. Scale bar = 200 μm. BMMs, bone marrow macrophages; DCF, 2\',7\'-dichlorofluorescein; GSR, glutathione-disulfide reductase; GTP, Guanosine-5\'-triphosphate; H~2~DCFDA, 2\',7\'-dichlorodihydrofluorescein diacetate; HO-1, heme oxygenase-1; NOX, nicotinamide adenine dinucleotide phosphate (NADPH) oxidase; Pse, Pseurotin A; Rac1, Ras-related C3 botulinum toxin substrate 1; RANKL, receptor activator of nuclear factor‐κB ligand; ROS, reactive oxygen species; TRAF6, TNF receptor-associated factor 6.](thnov09p1634g004){#F4}

![**Pse suppresses osteoclast differentiation by inhibiting the activation of NF-κB pathway, MAPK pathway, and NFATc1 signaling. (A)** Representative Western Blot images of the effects of Pse on IκBα degradation induced by RANKL. **(B)** Quantification of the ratios of band intensity of IκBα relative to β-actin (n=3 per group). **(C)** NF-κB luciferase assay showing that Pse inhibited NF-κB transcriptional activity dose-dependently (n=3 per group). **(D)** Representative Western Blot images of the effects of Pse on MAPKs pathway, including p-ERK, p-P38, and p-JNK. BMMs were pretreated with 10 μM Pse for 2 h prior to the addition of RANKL at the indicated time points and the indicated proteins were determined. **(E-G)** Quantification of the ratios of band intensity relative to ERK, P38, and JNK were analyzed (n=3 per group). **(H)** NFATc1 luciferase assay showing Pse significantly inhibited NFATc1 transcriptional activity (n=3 per group). **(I)** Representative Western Blot images of the expression levels of NFATc1 and osteoclast-related proteins including Integrin αV, Cathepsin K, and V-ATPase-d2 during osteoclastogenesis. BMMs were stimulated with RANKL in the absence or presence of 10 µM Pse for 0, 1, 3, and 5 days before protein collection for Western Blot. **(J-M)** Quantification of the ratios of band intensity of NFATc1, Integrin αV, Cathepsin K, and V-ATPase-d2 relative to β-actin (n=3 per group). All bar graphs are presented as mean ± SD. \*P\<0.05, \*\*P\<0.01 relative to RANKL-induced control group at the same time point. BMMs, bone marrow macrophages, MAPKs, mitogen-activated protein kinases; NFATc1, nuclear factor of activated T cells 1; NF-κB, nuclear factor-κB; Pse, Pseurotin A](thnov09p1634g005){#F5}

![**Pse treatment prevents ovariectomized (OVX)-induced bone loss in vivo. (A)** Schematic illustration of the establishment of OVX mouse model and the experimental design to evaluate Pse\'s therapeutic effects. **(B)** Representative μCT images showing that the bone loss was prevented by Pse administration. **(C-F)** Quantitative analyses of parameters regarding bone microstructure, including BV/TV, Tb.N, Conn.Dn, and Tb.Th (N=6 per group). **(G)** Representative images of HE staining of decalcified bone sections. **(H-I)** Quantitative analyses of BV/TV and BS in tissue sections (n=4 per group). All bar graphs are presented as mean ± SD. \*\*P\<0.01 relative to the OVX group. BS, bone surface; BV/TV, bone volume per tissue volume; Conn.Dn, connectivity density; HE, hematoxylin and eosin; NS, non-significant; Pse, Pseurotin A; TB, trabecular bone; Tb.N, trabecular number; Tb.Th, trabecular thickness](thnov09p1634g006){#F6}

![**Pse treatment reduces osteoclasts and ROS production in OVX mice. (A)** Representative images of TRAcP staining of decalcified bone sections. **(B-C)** Quantitative analyses of N.Oc/BS and Oc.S/B (n=4 per group). **(D)** Representative images of bone cryosections showing ROS fluorescence in different groups. **(E)** Quantitative analyses of ROS fluorescence intensity relative to sham group (n=5 per group). All bar graphs are presented as mean ± SD. \*\*P\<0.01 relative to the OVX+Vehicle group. BM, bone marrow; DAPI, 4,6-diamidino-2-phenylindole; DHE, dihydroethidium; GP, growth plate; ROS, reactive oxygen species; N.Oc/BS, osteoclast number/bone surface; Oc.S/BS, osteoclast surface/bone surface; TB, trabecular bone; TRAcP, tartrate resistant acid phosphatase](thnov09p1634g007){#F7}

![**A proposed scheme for the inhibition of Pse on osteoclastogenesis.** Upon RANKL binding to RANK, both NF-κB and MAPKs pathways are activated, leading to the amplification of NFATc1. Several osteoclast-specific genes such as *Ctsk*, *Acp5*, *Atp6v0d2*, and *Mmp9* are upregulated as a result. These signaling events are mediated by RANKL-induced ROS signaling. Our results demonstrated for the first time that Pse inhibits osteoclastogenesis via suppressing ROS level by inhibiting RANKL-induced ROS production and enhancing expression of antioxidant enzymes. *Acp5*, acid phosphatase 5, tartrate resistant; AP-1, activator protein 1; *Atp6v0d2*, ATPase H+ Transporting V0 Subunit D2; NFATc1, nuclear factor of activated T cells 1; *c-fos*, Proto-oncogene C-Fos; *Ctsk*, cathepsin K; *Mmp9,* matrix metallopeptidase 9; NOX, nicotinamide adenine dinucleotide phosphate oxidase; Pse, Pseurotin A; Rac1, Ras-related C3 botulinum toxin substrate 1; RANKL, receptor activator of nuclear factor‐κB (NF-κB) ligand; ROS, reactive oxygen species](thnov09p1634g008){#F8}

[^1]: \*Kai Chen and Pengcheng Qiu contributed equally to this work.

[^2]: Competing Interests: The authors have declared that no competing interest exists.
